Lucid Diagnostics Announced That The American Foregut Society Has Formally Requested That Health Insurance Providers Update Their Medical Policies To Include The EsoGuard Esophageal DNA Test As A Covered Service
Lucid Diagnostics Announced That The American Foregut Society Has Formally Requested That Health Insurance Providers Update Their Medical Policies To Include The EsoGuard Esophageal DNA Test As A Covered Service
Request for insurance coverage aims to enhance early detection and treatment of esophageal precancer to prevent highly lethal esophageal cancer
保险覆盖请求旨在增强食管癌前病变的早期检测和治疗，以预防高度致命的食管癌。
NEW YORK, Aug. 13, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that the American Foregut Society (AFS), a leading society of gastroenterologists and surgeons collaborating to improve patient outcomes, including in esophageal disease, has formally requested that health insurance providers update their medical policies to include the EsoGuard Esophageal DNA test as a covered service.
2024年8月13日，纽约 /美通社/ -- Lucid诊断公司（NASDAQ:LUCD）（“Lucid”或“公司”），一家致力于商业化的癌症预防医疗诊断公司，及PAVmed公司（NASDAQ:PAVM）的子公司，今天宣布，美国食管前协会（AFS）已正式要求健康保险提供商更新其医疗政策，将EsoGuard食管DNA检测作为覆盖服务。AFS是一家领先的胃肠专科医生和外科医生协作改善患者成果的协会，包括食管疾病。